Brief: UroGen receives FDA agreement on NDA submission strategy in Recurrent LG-IR-NMIBC based on UTOPIA Trial
06/11/2025 14:13
Nov 6 (Reuters) - Urogen Pharma Ltd UR8.F: UROGEN REPORTS 77.8% THREE-MONTH COMPLETE RESPONSE RATE FROM PHASE 3 UTOPIA TRIAL OF UGN-103 AND RECEIVES FDA AGREEMENT ON NDA SUBMISSION STRATEGY IN RECURRENT LG-IR-NMIBC BASED ON UTOPIA TRIAL Source text: ID:nGNX3JKcdK Further company coverage: UR8.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors